Today: 7 February 2026
Subscribe
Browse Category

NYSE:KOLD News 29 December 2025 - 4 February 2026

Natural gas prices rebound 5% as traders brace for Thursday’s EIA storage report

Natural gas prices rebound 5% as traders brace for Thursday’s EIA storage report

U.S. natural gas futures surged about 5% to $3.48 per mmBtu late Wednesday, rebounding after a sharp drop earlier this week. Leveraged ETFs BOIL and KOLD swung 7.5% higher and 8% lower, respectively. Analysts expect the Feb. 5 storage report to show a record 366 Bcf withdrawal after last week’s Arctic freeze. U.S. LNG exports fell slightly in January as plant outages hit supply.
4 February 2026
···
Natural gas price closes at $3.10 — what traders watch before markets reopen

Natural gas price closes at $3.10 — what traders watch before markets reopen

U.S. Henry Hub natural gas futures closed Friday at $3.103 per mmBtu, down 0.8% ahead of the MLK Day holiday. Federal data showed storage at 3,185 Bcf after a 71 Bcf withdrawal. Lower 48 output averaged 109.1 bcfd in January, while LNG feedgas held at 18.5 bcfd despite plant disruptions. Mitsubishi Corp agreed to buy Aethon Energy’s Haynesville Shale assets for $7.53 billion.
17 January 2026
···
Natural gas price stock: UNG jumps 7.5% as Henry Hub futures rebound — what traders watch next

Natural gas price stock: UNG jumps 7.5% as Henry Hub futures rebound — what traders watch next

Shares of the United States Natural Gas Fund (UNG) jumped 7.5% Monday to $11.18, then slipped 0.9% after-hours as U.S. natural gas futures surged on colder weather forecasts. NYMEX February gas closed at $3.409 per MMBtu, then dropped 2.1% in early Tuesday trading. Dry gas production remains near record highs. Gas-linked stocks and leveraged ETFs also moved sharply.
13 January 2026
····
Natural gas ETFs get hit as warm-weather outlook drags futures; UNG, BOIL, KOLD in focus

Natural gas ETFs get hit as warm-weather outlook drags futures; UNG, BOIL, KOLD in focus

U.S. natural gas futures fell 2.7% early Tuesday to $3.43/mmBtu, extending Monday’s 5% drop on warmer forecasts. UNG closed down 3.6%, BOIL lost 10.9%, and KOLD rose 11.2% Monday. Traders await Thursday’s storage data and mid-January weather updates. Lower 48 gas output held near 109–111 bcf/day, with LNG export flows near 19–20 bcf/day.
6 January 2026
·····
Natural gas price stock UNG slides as Henry Hub futures tumble 5% on warm U.S. outlook

Natural gas price stock UNG slides as Henry Hub futures tumble 5% on warm U.S. outlook

Shares of the United States Natural Gas Fund (UNG) dropped 4.1% to $11.57 Monday as U.S. natural gas futures slid 5.5% to $3.419 per mmBtu on warmer weather forecasts. Leveraged gas ETFs swung sharply, with BOIL down 11.5% and KOLD up 11.8%. Traders are watching Thursday’s U.S. storage report and mid-January weather updates.
5 January 2026
·····

Stock Market Today

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

7 February 2026
New York, Feb 7, 2026, 15:18 EST — Market closed. Philip Morris International shares last stood at $182.81, up 0.45% from the prior session, after the company laid out a higher 2026 profit outlook tied to its nicotine pouch business. (Reuters) That matters now because the stock has become a referendum on whether smoke-free products can keep carrying earnings while the category gets crowded. Zyn is the big swing factor, and traders are watching for any sign that volume gains are coming at the cost of pricing power. With U.S. markets shut for the weekend, the next test comes at
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop